glp-1 induced gastroparesis Gastrointestinal effects of receptor agonists: mechanisms, management, and future directions GLP-1 Receptor Agonists in Diabetes

NAD+ effects are reported over weeks to months of consistent supplementation

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) affects millions of people worldwide

,

They found that for FDA approved GLP-1s for weight loss, liraglutide (Saxenda) and semaglutide (Wegovy), the percent of side effects reported was as follows: Nausea: 42.2% Diarrhea: 21.9% Vomiting: also 21.9% Constipation: 8.4% They report that although the incidence of side effects were similar among medications, semaglutide had the greatest risk of nausea, diarrhea, and vomiting, whereas liraglutide had the greatest risk of upper abdominal pain

If you escalate after two weeks, you have not experienced the full effect of the lower dose

Lower energy during exercise: Reduced calorie intake may affect stamina early on